Literature DB >> 19756408

A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology.

Scott I Abrams1.   

Abstract

Understanding mechanisms of tumor escape are critically important not only to improving our knowledge of cancer biology, but also for the overall development of more effective anti-neoplastic therapies. Our laboratory focuses on mechanisms of apoptotic resistance, with emphasis on Fas loss of function as an important determinant of tumor progression. Our work in solid tumor systems has led to the identification of interferon regulatory factor-8 (IRF-8) as a differentially expressed gene important for tumor cell response to cytotoxicity, including Fas-mediated apoptosis and host-anti-tumor immunosurveillance mechanisms. Although IRF-8 was originally identified in the regulation of normal and neoplastic myeloid cell development, these findings revealed a new functional role for IRF-8 in non-hematopoietic malignancies and establish a molecular basis for its potential manipulation during cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19756408     DOI: 10.1007/s12026-009-8125-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  41 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations.

Authors:  Kebin Liu; Elwood McDuffie; Scott I Abrams
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

3.  IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages.

Authors:  Atsuko Masumi; Satoshi Tamaoki; I Ming Wang; Keiko Ozato; Katsutoshi Komuro
Journal:  FEBS Lett       Date:  2002-11-06       Impact factor: 4.124

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  IFN-gamma up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages.

Authors:  Y M Kim; J Y Im; S H Han; H S Kang; I Choi
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

6.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

Review 7.  Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.

Authors:  Scott I Abrams
Journal:  Front Biosci       Date:  2005-01-01

8.  Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Authors:  Dongshu Chen; Jianchuan Xia; Yasuhiro Tanaka; Hongsong Chen; Shigeo Koido; Oliver Wernet; Pinku Mukherjee; Sandra J Gendler; Donald Kufe; Jianlin Gong
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

9.  Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas.

Authors:  K Y Lee; H Geng; K M Ng; J Yu; A van Hasselt; Y Cao; Y-X Zeng; A H Y Wong; X Wang; J Ying; G Srivastava; M L Lung; L-D Wang; T T Kwok; B-Z Levi; A T C Chan; J J Y Sung; Q Tao
Journal:  Oncogene       Date:  2008-05-12       Impact factor: 9.867

10.  Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma.

Authors:  Kebin Liu; Scott I Abrams
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

View more
  8 in total

1.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

2.  IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.

Authors:  Jinxia Liang; Feng Lu; Bo Li; Lu Liu; Guandi Zeng; Qian Zhou; Liang Chen
Journal:  Cell Cycle       Date:  2019-10-09       Impact factor: 4.534

Review 3.  Transcriptional regulation of myeloid-derived suppressor cells.

Authors:  Thomas Condamine; Jérôme Mastio; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2015-09-03       Impact factor: 4.962

4.  IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

Authors:  Fabrizio Mattei; Giovanna Schiavoni; Paola Sestili; Francesca Spadaro; Alessandra Fragale; Antonella Sistigu; Valeria Lucarini; Massimo Spada; Massimo Sanchez; Stefania Scala; Angela Battistini; Filippo Belardelli; Lucia Gabriele
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

5.  Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.

Authors:  Debarati Banik; A Nazmul H Khan; Even Walseng; Brahm H Segal; Scott I Abrams
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

6.  The dual role of IRF8 in cancer immunosurveillance.

Authors:  Giovanna Schiavoni; Lucia Gabriele; Fabrizio Mattei
Journal:  Oncoimmunology       Date:  2013-07-01       Impact factor: 8.110

7.  IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling.

Authors:  Ding-Sheng Jiang; Xiang Wei; Xiao-Fei Zhang; Yu Liu; Yan Zhang; Ke Chen; Lu Gao; Heng Zhou; Xue-Hai Zhu; Peter P Liu; Wayne Bond Lau; Xinliang Ma; Yunzeng Zou; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

8.  Hypermethylation of Interferon Regulatory Factor 8 (IRF8) Confers Risk to Vogt-Koyanagi-Harada Disease.

Authors:  Yiguo Qiu; Hongsong Yu; Yunyun Zhu; Zi Ye; Jing Deng; Wencheng Su; Qingfeng Cao; Gangxiang Yuan; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.